「停用ITP患者TPO-RA」研究:罗米司亭减量的临床与免疫调节效应
STIP是一项前瞻性试验,40例成人ITP患者中22例接受罗米司亭治疗1年后减量并随访1年,减量后1年持续停药缓解(SROT)概率为23.6%(95%CI 11.0%-50.5%);SROT者减量开始时血小板水平更高、罗米司亭剂量更低,部分患者抗血小板抗体下降、血小板存活改善。
要点
- 减量后1年SROT概率为23.6%(95%CI 11.0%-50.5%)。
- SROT者减量开始时血小板中位数332.5 vs 非持续缓解者84.5×10^9/L。
- SROT者减量开始时罗米司亭剂量中位数1.0 vs 非持续缓解者4.5 μg/kg。
核心结论
- STIP研究在多样化且大多为慢性的成人ITP患者中显示,减量后1年SROT概率为23.6%(95%CI 11.0%-50.5%)。
研究设计与样本
- STIP是一项前瞻性试验,旨在探讨罗米司亭减量的临床效应。
- 40例成人ITP患者中22例接受罗米司亭治疗1年,随后减量并随访1年。
- 在罗米司亭治疗前、治疗期间及治疗后评估抗血小板抗体(APA)、TPO水平和铟-111血小板闪烁显像。
主要发现
- 截尾生存分析显示,减量后1年SROT概率为23.6%(95%CI 11.0%-50.5%)。
- SROT者罗米司亭治疗期间血小板中位数332.5 vs 非持续缓解(NSR)者84.5×10^9/L。
- SROT者减量开始时罗米司亭剂量中位数1.0 vs NSR者4.5 μg/kg。
- 基线时8/25例检出APA,其中5例在罗米司亭治疗期间显著下降。
- 铟-111扫描显示,减量开始时SROT者中50%(2/4,缺失n=1)血小板存活改善,而NSR者中为0%(0/14,缺失n=3)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sustained remissions off-treatment (SROTs) after tapering of thrombopoietin receptor agonists (TPO-RAs) have been reported in 15%-50% of patients with immune thrombocytopenia (ITP). The STIP (Stop TPO-Receptor Agonist in ITP Patients) study is a prospective trial aimed to investigate the clinical effects of romiplostim tapering. Adult patients (22/40) with ITP ≥3 months received romiplostim for 1 year, were tapered and followed for 1 year. Anti-platelet antibodies (APAs), TPO levels and indium-111 platelet scintigraphy were assessed before, during and after romiplostim. Censored survival analysis showed that the probability of SROT at 1 year after tapering was 23.6% (95% confidence interval: 11.0%-50.5%). Patients with SROT had higher platelet levels on romiplostim (median: 332.5 vs. 84.5 × 109/L) and lower romiplostim doses at the start of tapering (median: 1.0 vs. 4.5 μg/kg) compared to those with a non-sustained response (NSR). APAs were detected in 8/25 patients at baseline, of which 5 showed a substantial decrease during romiplostim. The indium-111 scan revealed an improved platelet survival at the start of tapering for 50% of patients with SROT (2/4, missing n = 1) versus none with an NSR (0/14, missing n = 3). Overall, the STIP study demonstrated a probability of SROT of 23.6% in a diverse and largely chronic group of adult patients with ITP.
引用
- Nelson VS, Amini SN, Netelenbos T, et al. The 'Stop TPO-RA in ITP Patients' study: Clinical and immune modulatory effects of romiplostim tapering. Br J Haematol. 2025. PMID: 40384450. doi:10.1111/bjh.20100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。